期刊文献+

单唾液酸四己糖神经节苷酯治疗帕金森病临床观察

原文传递
导出
摘要 帕金森病(Parkinson disease,PD)是一种黑质致密层多巴胺能神经元的慢性进行性老年变性疾病,严重影响到患者的健康和生存能力。临床以震颤、强直、运动迟缓为主要表现,目前尚无有效药物能阻止神经元的变性,使病情逆转。
出处 《江苏医药》 CAS CSCD 北大核心 2012年第16期1967-1968,共2页 Jiangsu Medical Journal
  • 相关文献

参考文献5

二级参考文献10

  • 1Mullya VV,Heinonen EH,Vuorinrn JA,et al. Early selegiline therapy reduces levodopa dose requirement in Parkinson's disease[J]. Acta Neurol Stand, 1995,91(3) : 177-182.
  • 2Przuntek H,Conrad B, Dichgans M,et al. SELEDO: a 5-year long term trial on the effect of selegine in early Parkinsonian patients treated with levodopa[J]. Eur J Neurol, 1999,6 (2) : 141-150.
  • 3Ebadi M,Sharma S,Shevali S,et al. Neuroprotective actions of selegiline[J]. J Neurosci Res, 2002,67(3) : 285-289.
  • 4Avrova NF, Shestak KI, Zakharova IO, et al. The use of antioxidants to prevent glutamate induced derangement of calcium ion metabolism in rat cerebral cortex synaptosomes. Neurosci Behav Physiol, 2000,30(5) :535-541.
  • 5Schneider JS. GM1 ganglioside in the treatment of Parkinson's disease. Ann NY Acad Sci, 1998,845 : 363-373.
  • 6Woodgate A, Macgibbon G, walton M, et al. The toxicity of 6-hydroxydopamine on PC12 and P19 cells. Brain Res Mol Brain Res,1999,69(1) :84.
  • 7Maruyama W, Yamamoto T, Kitani K, et al. Mechanism underlying anti-apoptotic activity of a deprenyl,related propargylamine, rasagiline. Mech Ageing Dev,2000,116(2-3) : 18.
  • 8Miyashita T, Krajewska M, Wang H, et al. Tumor suppressor p53 is a regulator.of bcl-2 and bax gene expression in vitro and in vivo.Oncogene, 1994, 9 : 1799-1805.
  • 9Schneider JS, Roeltgen DP, Rothblat DS, et al. GM1 ganglioside treatment of Parkinson's disease': an open pilot study of Safety and efficacy. Neurology, 1995,45 : 1149-1154.
  • 10张克忠,蒋雨平.单胺氧化酶B抑制剂在治疗帕金森病中的研究[J].中国临床神经科学,2008,16(2):179-182. 被引量:12

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部